Ascelia Pharma Logo

Ascelia Pharma

ACE | ST

Overview

Corporate Details

ISIN(s):
SE0010573113 (+2 more)
LEI:
5493002YR9VCJJPWYN08
Country:
Sweden
Address:
Hyllie Boulevard 34, 215 32 Malmö
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Ascelia Pharma is a biotechnology company dedicated to the development and commercialization of novel drugs for rare cancer conditions (orphan oncology). The company's vision is to address unmet medical needs by advancing a portfolio of innovative therapies with clear development and market pathways. Its lead product candidate, Orviglance, is a novel manganese-based oral contrast agent for magnetic resonance imaging (MRI) designed to improve the detection of liver metastases in cancer patients with severely impaired kidney function, for whom gadolinium-based agents are contraindicated. The company is focused on progressing its pipeline through clinical development and towards regulatory approval.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Ascelia Pharma. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-21 07:30
Interim Report
Swedish 4.5 MB
2025-08-21 07:30
Interim Report
English 4.4 MB
2025-05-16 07:30
Interim Report
Swedish 4.4 MB
2025-05-16 07:30
Investor Presentation
English 4.4 MB
2025-05-07 16:30
Post-Annual General Meeting Information
Kommuniké från årsstämma den 7 maj 2025 i Ascelia Pharma AB
Swedish 193.2 KB
2025-05-07 16:30
Post-Annual General Meeting Information
Bulletin from the Annual General Meeting in Ascelia Pharma AB on 7 May 2025
English 192.7 KB
2025-04-30 11:30
Declaration of Voting Results & Voting Rights Announcements
Change in Number of Shares and Votes in Ascelia Pharma AB
English 185.4 KB
2025-04-30 11:30
Declaration of Voting Results & Voting Rights Announcements
Ändring av antalet aktier och röster i Ascelia Pharma AB
Swedish 185.6 KB
2025-03-18 22:05
Legal Proceedings Report
Ascelia Pharma meddelar positivt utfall från FDA-möte och bekräftar planen att …
Swedish 190.7 KB
2025-03-18 22:05
Legal Proceedings Report
Ascelia Pharma Announces Positive Outcomes of FDA Meeting and Confirms Plan to …
English 190.5 KB
2025-02-25 14:45
Post-Annual General Meeting Information
Kommuniké från extra bolagsstämma den 25 februari 2025 i Ascelia Pharma AB
Swedish 191.1 KB
2025-02-25 14:45
Post-Annual General Meeting Information
Bulletin from the Extraordinary General Meeting in Ascelia Pharma AB on 25 Febr…
English 190.5 KB
2025-02-12 21:30
Board/Management Information
Nomination Committee Appointed for AGM 2025 in Ascelia Pharma AB
English 191.2 KB
2025-02-12 21:30
Pre-Annual General Meeting Information
Valberedning utsedd i Ascelia Pharma AB inför årsstämman 2025
Swedish 191.0 KB
2025-02-07 07:30
Annual / Quarterly Financial Statement
Swedish 4.0 MB

Automate Your Workflow. Get a real-time feed of all Ascelia Pharma filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Ascelia Pharma via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-04-22 Marie Birgitta Källström Other Other 18,752 40,316.80 SEK
2025-04-15 Niels Mengel Other Other 92,304 198,453.60 SEK
2025-04-15 Peter Benson Other Other 50,000 107,500.00 SEK
2025-04-15 Carin Linde Other Other 40,328 86,705.20 SEK
2025-04-15 Peter Benson Other Other 21,688 46,629.20 SEK
2025-04-15 Peter Benson Other Other 20,472 44,014.80 SEK
2025-04-15 Julie Brogren Other Other 18,000 38,700.00 SEK
2025-04-15 Peter Benson Other Other 6,152 13,226.80 SEK
2024-09-03 KIBEGEON Other Sell 913,545 150,917.63 SEK
2024-09-03 Niels Mengel Other Sell 131,965 17,815.28 SEK

Peer Companies

Company Country Ticker View
1NKEMIA Logo
Offers contract R&D, develops tech platforms, and invests in life sciences ventures.
Spain IKM
2cureX AB Logo
Tests cancer drugs on patient-derived micro-tumors for personalized oncology treatments.
Sweden 2CUREX
4SC AG Logo
Developing epigenetic small-molecule drugs for cancers with high unmet medical needs.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using an OMV platform for major infectious diseases.
Sweden ABERA
ABIVAX Logo
Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.
France ABVX
Abliva Logo
A clinical-stage biotech developing medicines for rare primary mitochondrial diseases.
Sweden ABLI
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland ACHI
Acticor Biotech Logo
Biopharma developing first-in-class drugs for acute stroke and other thrombotic diseases.
France ALACT
Active Biotech Logo
Develops immunotherapies for cancer and inflammatory diseases with significant unmet needs.
Sweden ACTI
Addex Therapeutics Ltd Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland ADXN